Recruiting studies: Pheochromocytoma Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
Phase 2 · 1 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT07680205 Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06427798 Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024 [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors,
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06479811 Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Phase 1/Phase 2 · 19 location(s) · Perspective Therapeutics · NCT05636618 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Ma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT00107289

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.